{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:42Z","timestamp":1789725942497,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population.<\/jats:p>\n                  <jats:p>Clinical trial registration VIKING-3: ClinicalTrials.gov identification number, NCT01328041; URL, https:\/\/clinicaltrials.gov\/study\/NCT01328041; BRIGHTE: ClinicalTrials.gov identification number, NCT02362503; URL, https:\/\/clinicaltrials.gov\/study\/NCT02362503<\/jats:p>","DOI":"10.1093\/ofid\/ofag487","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:57:06Z","timestamp":1786017426000},"source":"Crossref","is-referenced-by-count":0,"title":["Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens"],"prefix":"10.1093","volume":"13","author":[{"given":"Antonella","family":"Castagna","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Vita-Salute San Raffaele University , Milan ,","place":["Italy"]},{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Marcon","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Du","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Wang","sequence":"additional","affiliation":[{"name":"GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-9624","authenticated-orcid":false,"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Donovan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-367X","authenticated-orcid":false,"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Prakash","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026091805314972900_ofag487-B1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/phar.2913","article-title":"Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and\/or have multidrug-resistant HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: an executive summary","volume":"44","author":"Cluck","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2026091805314972900_ofag487-B2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/biomedicines12040915","article-title":"The phenomenon of antiretroviral drug resistance in the context of human immunodeficiency virus treatment: dynamic and ever evolving subject matter","volume":"12","author":"Apetroaei","year":"2024","journal-title":"Biomedicines"},{"key":"2026091805314972900_ofag487-B3","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-9-1","article-title":"HIV: how to manage heavily treatment-experienced patients","volume":"11","author":"Spivack","year":"2022","journal-title":"Drugs Context"},{"key":"2026091805314972900_ofag487-B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106493","article-title":"Management of comorbidities in treated HIV infection: a long way to go: HIV, comorbidities and aging","volume":"59","author":"Mart\u00ednez-Sanz","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026091805314972900_ofag487-B5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1133407","article-title":"Strategies to overcome HIV drug resistance-current and future perspectives","volume":"14","author":"Temereanca","year":"2023","journal-title":"Front Microbiol"},{"key":"2026091805314972900_ofag487-B6","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/infdis\/jix137","article-title":"Global HIV antiretroviral drug resistance: a perspective and report of a National Institute of Allergy and Infectious Diseases Consultation","volume":"216","author":"Godfrey","year":"2017","journal-title":"J Infect Dis"},{"key":"2026091805314972900_ofag487-B7","author":"World Health Organization (WHO)"},{"key":"2026091805314972900_ofag487-B8","doi-asserted-by":"crossref","first-page":"13596535231201162","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective","volume":"28","author":"Carr","year":"2023","journal-title":"Antivir Ther"},{"key":"2026091805314972900_ofag487-B9","author":"Unitaid"},{"key":"2026091805314972900_ofag487-B10","author":"World Health Organization"},{"key":"2026091805314972900_ofag487-B11","author":"HIV.gov"},{"key":"2026091805314972900_ofag487-B12","volume-title":"EACS Guidelines. Version 13.0","author":"European AIDS Clinical Society","year":"2025"},{"key":"2026091805314972900_ofag487-B13","doi-asserted-by":"crossref","first-page":"107883","DOI":"10.1016\/j.ijid.2025.107883","article-title":"Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation","volume":"155","author":"Gagliardini","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026091805314972900_ofag487-B14","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026091805314972900_ofag487-B15","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir\u2014a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"Kandel","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026091805314972900_ofag487-B16","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"2026091805314972900_ofag487-B17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"2026091805314972900_ofag487-B18","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s40121-023-00870-6","article-title":"Week 240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1","volume":"12","author":"Aberg","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026091805314972900_ofag487-B19","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01751-21","article-title":"Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1","volume":"66","author":"Gartland","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314972900_ofag487-B20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/v16020239","article-title":"HIV-1 drug resistance detected by next-generation sequencing among ART-na\u00efve individuals: a systematic review and meta-analysis","volume":"16","author":"Ouyang","year":"2024","journal-title":"Viruses"},{"key":"2026091805314972900_ofag487-B21","volume-title":"WHO Updated recommendations on HIV clinical management: recommendations for a public health approach","year":"2025"},{"key":"2026091805314972900_ofag487-B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2026091805314972900_ofag487-B23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1394644","article-title":"Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study","volume":"15","author":"Llibre","year":"2024","journal-title":"Front Immunol"},{"key":"2026091805314972900_ofag487-B24","volume-title":"TIVICAY (Dolutegravir) [package insert]","year":"2013"},{"key":"2026091805314972900_ofag487-B25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae469","article-title":"Inflammatory biomarker reduction with fostemsavir over 96 weeks in heavily treatment-experienced adults with multidrug-resistant HIV-1 in the BRIGHTE study","volume":"11","author":"Clark","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026091805314972900_ofag487-B26","author":"Aberg"},{"key":"2026091805314972900_ofag487-B27","author":"Dyson"},{"key":"2026091805314972900_ofag487-B28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.clinthera.2022.04.007","article-title":"Comparative efficacy and safety of fostemsavir in heavily treatment-experienced people with HIV-1","volume":"44","author":"Anderson","year":"2022","journal-title":"Clin Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag487\/70554928\/ofag487.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag487\/70554928\/ofag487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag487\/70554928\/ofag487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:12Z","timestamp":1789723932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag487\/8756899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag487","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,8]]},"article-number":"ofag487"}}